News

Alnylam Pharmaceuticals (ALNY) is up 3.6% today. Here is some analysis on what might have caused this price movement.Analysis: The move appears tied to a mix of…

DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the AL amyloidosis,…

Patients with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who were alive 2 years after tafamidis initiation had a less advanced disease…

A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who carry the most common TTR gene mutation that causes…

AbstractAcoramidis is a novel transthyretin stabilizer recently approved for the treatment of transthyretin amyloid cardiomyopathy. Although clinical trials showed…

Aims To evaluate the applicability of the RoMa classification in patients with transthyretin cardiac amyloidosis (ATTR-CM) and to assess its association with…

AbstractBackground: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality…

Background and Objectives: Amyloidosis is a systemic disorder characterized by extracellular deposition of misfolded protein fibrils, most commonly light-chain (AL…

Vutrisiran demonstrated consistent efficacy in both women and men with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), with no statistically significant…

AbstractIntroductionIgD-associated AL amyloidosis is a rare subtype, accounting for 1–2% of cases, with fewer than 100 reported. Prior studies show inconsistent…